Related Experiment Video
Updated: Jul 18, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
MDM2 T309G polymorphism is associated with bladder cancer.
Onur Emre Onat1, Mesut Tez, Tayfun Ozçelik
1Department of Molecular Biology and Genetics, Bilkent University, Bilkent, Ankara 06800, Turkey.
Anticancer Research
|November 11, 2006
Summary
The MDM2 T309G polymorphism, affecting gene expression, is linked to increased bladder cancer risk. Specifically, the G/G genotype showed a 2.68-fold higher risk in a Turkish study group.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- The MDM2 gene regulates the tumor suppressor p53.
- A T to G polymorphism (SNP 309, rs: 2279744) in the MDM2 promoter affects its expression.
- This polymorphism's role in bladder cancer risk is under investigation.
Purpose of the Study:
- To investigate the association between the MDM2 T309G polymorphism and bladder cancer susceptibility.
- To determine if the MDM2 T309G polymorphism is a genetic risk factor for bladder cancer.
Main Methods:
- A case-control study was conducted.
- The study included 75 bladder cancer patients and 103 healthy controls from Turkey.
- Genotyping for the MDM2 T309G polymorphism was performed.
Main Results:
- The G/G genotype of the MDM2 T309G polymorphism was associated with an increased risk of bladder cancer.
- Individuals with the G/G genotype had a 2.68-fold increased risk (95% CI, 1.34-5.40) compared to T/T and T/G genotypes.
- This suggests a significant association between MDM2 T309G polymorphism and bladder cancer.
Conclusions:
- The MDM2 T309G polymorphism may be a potential genetic susceptibility factor for bladder cancer.
- This is the first study to report this association in a Turkish population.
- Further research is warranted to confirm these findings in diverse populations.
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:20Mismatch Repair
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:36Mismatch Repair
Overview